Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Mengyao, Sheng, Jianpeng, Zhang, Qi, Wang, Jianxin, Fu, Qihan, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016350/
https://www.ncbi.nlm.nih.gov/pubmed/36937383
http://dx.doi.org/10.3389/fonc.2023.1118633
_version_ 1784907389807362048
author Dai, Mengyao
Sheng, Jianpeng
Zhang, Qi
Wang, Jianxin
Fu, Qihan
Liang, Tingbo
author_facet Dai, Mengyao
Sheng, Jianpeng
Zhang, Qi
Wang, Jianxin
Fu, Qihan
Liang, Tingbo
author_sort Dai, Mengyao
collection PubMed
description Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket trial. However, no pancreatic cancer patients were enrolled in that trial. Whether pancreatic cancer patients with high TMB respond to PD-1 blockade as well remains unclear. Here, we report a case with a partial response to single-agent immunotherapy with pembrolizumab in pancreatic cancer with high TMB after the failure of several lines of chemotherapy. This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. In addition, in order to understand the basic immune state of our patients, we also analyzed the changes in immune cells in peripheral blood with cytometry by time-of-flight mass spectrometry (CyTOF) before and after pembrolizumab treatment.
format Online
Article
Text
id pubmed-10016350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100163502023-03-16 Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden Dai, Mengyao Sheng, Jianpeng Zhang, Qi Wang, Jianxin Fu, Qihan Liang, Tingbo Front Oncol Oncology Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket trial. However, no pancreatic cancer patients were enrolled in that trial. Whether pancreatic cancer patients with high TMB respond to PD-1 blockade as well remains unclear. Here, we report a case with a partial response to single-agent immunotherapy with pembrolizumab in pancreatic cancer with high TMB after the failure of several lines of chemotherapy. This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. In addition, in order to understand the basic immune state of our patients, we also analyzed the changes in immune cells in peripheral blood with cytometry by time-of-flight mass spectrometry (CyTOF) before and after pembrolizumab treatment. Frontiers Media S.A. 2023-03-01 /pmc/articles/PMC10016350/ /pubmed/36937383 http://dx.doi.org/10.3389/fonc.2023.1118633 Text en Copyright © 2023 Dai, Sheng, Zhang, Wang, Fu and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Dai, Mengyao
Sheng, Jianpeng
Zhang, Qi
Wang, Jianxin
Fu, Qihan
Liang, Tingbo
Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title_full Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title_fullStr Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title_full_unstemmed Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title_short Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
title_sort case report: partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016350/
https://www.ncbi.nlm.nih.gov/pubmed/36937383
http://dx.doi.org/10.3389/fonc.2023.1118633
work_keys_str_mv AT daimengyao casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden
AT shengjianpeng casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden
AT zhangqi casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden
AT wangjianxin casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden
AT fuqihan casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden
AT liangtingbo casereportpartialresponsetosingleagentpembrolizumabinachemotherapyresistantmetastaticpancreaticcancerpatientwithahightumormutationburden

Ejemplares similares